An automated portable artificial kidney could effectively eliminate toxins from the blood of patients with kidney failure.
This invention was unveiled during the ASN Kidney Week 2019, which took place at the beginning of November at the Walter E. Washington Convention Center in Washington, D.C.
A world-first, the AWAK PD is a wearable and ultra-portable peritoneal dialysis (PD) system that incorporates a patented sorbent technology to disrupt the way in which peritoneal dialysis is currently administered. The AWAK PD is a compact device that weighs less than 2 kg and enables dialysis to be performed “on-the-go,” overcoming the challenge of long hours of therapy and connection to large-size dialysis machines in hospitals and clinics currently faced by renal patients.
A regenerative absorption technology present in artificial kidney therapy allows high-dose dialysis to be administered with a low volume of dialysis solution.
The sorbent technology regenerates and reconstitutes used dialysis fluid into fresh fluid while removing the uremic toxins from the spent dialysate. The device requires only between 1.5 and 2 liters of dialysate to perform a patient’s entire daily therapy, compared with 8 to 12 liters required by traditional PD methods.
In a first study in humans, 15 participants underwent more than 100 dialysis sessions with the device, without any adverse effects being recorded for a month-long treatment, and the sessions were effective in removing waste substances from the blood.
Suresha Venkataraya, Chief Executive Officer, AWAK Technologies, said:
“We are excited by the encouraging results from this important Phase I (first-in-human) trial of AWAK PD. The findings provide positive clinical evidence of AWAK PD’s safety profile as a wearable device with the potential to truly disrupt the administration of peritoneal dialysis treatments…
“The AWAK PD has been designed to empower ESRD patients to take control of their treatment in their own time and adapt therapy to their lifestyle rather than the other way around. We look forward to continuing our clinical work and commercializing our technology, offering an enhanced quality of life to end-stage renal disease patients worldwide.”